- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 88,020 | 29.05.24 17:35:36 | -0,580 | -0,65% | 0,000 | 0,000 | 88,450 | 88,600 |
|
Regeneron Pharmaceuticals | 881535 | NASDAQ | 967,350 | 29.05.24 21:50:08 | -5,810 | -0,60% | 966,230 | 967,700 | 970,000 | 973,160 |
